A Computational Workflow for Probabilistic Quantitative in Vitro to in Vivo Extrapolation

A computational workflow was developed to facilitate the process of quantitative in vitro to in vivo extrapolation (QIVIVE), specifically the translation of in vitro concentration-response to in vivo dose-response relationships and subsequent derivation of a benchmark dose value (BMD). The workflow integrates physiologically based pharmacokinetic (PBPK) modeling; global sensitivity analysis (GSA), Approximate Bayesian Computation (ABC) and Markov Chain Monte Carlo (MCMC) simulation. For a given set of in vitro concentration and response data the algorithm returns the posterior distribution of the corresponding in vivo, population-based dose-response values, for a given route of exposure. The novel aspect of the workflow is a rigorous statistical framework for accommodating uncertainty in both the parameters of the PBPK model (both parameter uncertainty and population variability) and in the structure of the PBPK model itself recognizing that the model is an approximation to reality. Both these sources of uncertainty propagate through the workflow and are quantified within the posterior distribution of in vivo dose for a fixed representative in vitro concentration. To demonstrate this process and for comparative purposes a similar exercise to previously published work describing the kinetics of ethylene glycol monoethyl ether (EGME) and its embryotoxic metabolite methoxyacetic acid (MAA) in rats was undertaken. The computational algorithm can be used to extrapolate from in vitro data to any organism, including human. Ultimately, this process will be incorporated into a user-friendly, freely available modeling platform, currently under development, that will simplify the process of QIVIVE.

[1]  Edward J. Perkins,et al.  Physiological fidelity or model parsimony? The relative performance of reverse-toxicokinetic modeling approaches , 2017, BMC Systems Biology.

[2]  Bas J Blaauboer,et al.  Relative developmental toxicity of glycol ether alkoxy acid metabolites in the embryonic stem cell test as compared with the in vivo potency of their parent compounds. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Michael A. Gallo,et al.  Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models , 1994 .

[4]  Karline Soetaert,et al.  Solving Differential Equations in R: Package deSolve , 2010 .

[5]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.

[6]  Radford M. Neal.  Optimal Proposal Distributions and Adaptive MCMC , 2008 .

[7]  Karline Soetaert,et al.  Inverse Modelling, Sensitivity and Monte Carlo Analysis in R Using Package FME , 2010 .

[8]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[9]  Bing Liu,et al.  Reconstructing exposures from small samples using physiologically based pharmacokinetic models and multiple biomarkers , 2009, Journal of Exposure Science and Environmental Epidemiology.

[10]  Andrew Gelman,et al.  Handbook of Markov Chain Monte Carlo , 2011 .

[11]  Andrew Worth,et al.  Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods , 2017, Computational toxicology.

[12]  R. Woutersen,et al.  Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose–response curves for developmental toxicity of phenol in rat and human , 2013, Archives of Toxicology.

[13]  Cécile Legallais,et al.  Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. , 2012, Analytical chemistry.

[14]  Andreas Huth,et al.  Statistical inference for stochastic simulation models--theory and application. , 2011, Ecology letters.

[15]  Yanan Fan,et al.  Likelihood-Free MCMC , 2011 .

[16]  Ans Punt,et al.  Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols , 2016, Archives of Toxicology.

[17]  Kevin McNally,et al.  A Workflow for Global Sensitivity Analysis of PBPK Models , 2011, Front. Pharmacol..

[18]  Jerry L. Campbell,et al.  Quantitative interpretation of human biomonitoring data. , 2008, Toxicology and applied pharmacology.

[19]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[20]  Imran Shah,et al.  Toxicokinetic Triage for Environmental Chemicals. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  B. van Ravenzwaay,et al.  Use of physiologically based kinetic modeling-facilitated reverse dosimetry of in vitro toxicity data for prediction of in vivo developmental toxicity of tebuconazole in rats. , 2017, Toxicology letters.

[22]  Jochem Louisse,et al.  Use of Physiologically Based Kinetic Modeling-Based Reverse Dosimetry to Predict in Vivo Toxicity from in Vitro Data. , 2017, Chemical research in toxicology.

[23]  F Y Bois,et al.  Statistical issues in toxicokinetic modeling: a bayesian perspective. , 2000, Environmental health perspectives.

[24]  Anna Forsby,et al.  In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities , 2016, Archives of Toxicology.

[25]  C Eric Hack,et al.  Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models. , 2006, Toxicology.

[26]  Liesbeth Geraets,et al.  Proper knowledge on toxicokinetics improves human hazard testing and subsequent health risk characterisation. A case study approach. , 2013, Regulatory toxicology and pharmacology : RTP.

[27]  Fredrik U. Jönsson,et al.  Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. , 2001, Toxicology.

[28]  Marie Laure Delignette-Muller,et al.  Evaluating variability and uncertainty separately in microbial quantitative risk assessment using two R packages. , 2010, International journal of food microbiology.

[29]  R. Iman,et al.  A distribution-free approach to inducing rank correlation among input variables , 1982 .

[30]  George Loizou,et al.  Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation , 2012, Journal of toxicology.

[31]  Harvey J Clewell,et al.  Development of a Screening Approach to Interpret Human Biomonitoring Data on Volatile Organic Compounds: Reverse Dosimetry on Biomonitoring Data for Trichloroethylene , 2007, Risk analysis : an official publication of the Society for Risk Analysis.

[32]  Harvey J Clewell,et al.  The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.

[33]  Robert G. Pearce,et al.  Evaluation and calibration of high-throughput predictions of chemical distribution to tissues , 2017, Journal of Pharmacokinetics and Pharmacodynamics.

[34]  Scott A. Sisson,et al.  Reversible Jump MCMC , 2011 .

[35]  J. Haycock,et al.  State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. , 2014, ALTEX.

[36]  B. Jönsson.  Disruptive innovation and EU health policy , 2017, The European Journal of Health Economics.

[37]  R. Woutersen,et al.  Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Thomas Hartung,et al.  Perspectives on In Vitro to In Vivo Extrapolations. , 2017, Applied in vitro toxicology.

[39]  Hadley Wickham,et al.  Reshaping Data with the reshape Package , 2007 .

[40]  Harvey J Clewell,et al.  Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.

[41]  Harvey J Clewell,et al.  PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.

[42]  Ans Punt,et al.  Non-animal approaches for toxicokinetics in risk evaluations of food chemicals. , 2017, ALTEX.

[43]  Jim E Riviere,et al.  Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From acslX to Berkeley Madonna, MATLAB, and R Language: Oxytetracycline and Gold Nanoparticles As Case Examples. , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[44]  B. K. Nelson,et al.  Comparative inhalation teratogenicity of four glycol ether solvents and an amino derivative in rats. , 1984, Environmental health perspectives.

[45]  R. Woutersen,et al.  Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation , 2012, Expert opinion on drug metabolism & toxicology.

[46]  Thomas Hartung,et al.  Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells , 2017, Archives of Toxicology.

[47]  Thomas Hartung,et al.  Are in vitro tests suitable for regulatory use? , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[48]  Thomas Hartung,et al.  Correlating in vitro data to in vivo findings for risk assessment. , 2014, ALTEX.

[49]  Bas J Blaauboer,et al.  The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  R. Conolly,et al.  Development of a physiologically based pharmacokinetic model of 2-methoxyethanol and 2-methoxyacetic acid disposition in pregnant rats. , 2000, Toxicology and applied pharmacology.

[51]  A. Roy,et al.  Reconstructing week-long exposures to volatile organic compounds using physiologically based pharmacokinetic models. , 1998, Journal of exposure analysis and environmental epidemiology.

[52]  Arthur N. Mayeno,et al.  Computational Toxicology of Chloroform: Reverse Dosimetry Using Bayesian Inference, Markov Chain Monte Carlo Simulation, and Human Biomonitoring Data , 2008, Environmental health perspectives.

[53]  Kevin McNally,et al.  PopGen: A virtual human population generator. , 2014, Toxicology.

[54]  Kevin McNally,et al.  A probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE , 2015, Front. Pharmacol..

[55]  I. Rietjens,et al.  In vitro‐in silico‐based analysis of the dose‐dependent in vivo oestrogenicity of the soy phytoestrogen genistein in humans , 2017, British journal of pharmacology.

[56]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[57]  George Loizou,et al.  Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[58]  M. Toraason,et al.  Electrocardiographic study of rat fetuses exposed to ethylene glycol monomethyl ether (EGME). , 1985, Teratology.

[59]  D. Paustenbach,et al.  A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human. , 2000, Toxicology and applied pharmacology.